Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India
· Delayed Price · Currency is INR 2,181.10
+277.10 (14.55%)
Jul 11, 2025, 3:30 PM IST
Glenmark Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, Glenmark Pharmaceuticals had annual revenue of 134.35B INR with 6.25% growth. Glenmark Pharmaceuticals had revenue of 32.68B in the quarter ending March 31, 2025, a decrease of -16.11%.
Revenue
134.35B
Revenue Growth
+6.25%
P/S Ratio
4.58
Revenue / Employee
8.96M
Employees
14,989
Market Cap
615.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 134.35B | 7.90B | 6.25% |
| Mar 31, 2024 | 126.45B | 9.90B | 8.49% |
| Mar 31, 2023 | 116.56B | -6.49B | -5.28% |
| Mar 31, 2022 | 123.05B | 13.61B | 12.44% |
| Mar 31, 2021 | 109.44B | 2.87B | 2.69% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Glenmark Pharmaceuticals News
- 23 hours ago - Glenmark Pharma receives warning letter from US FDA for Indore facility - Business Upturn
- 2 days ago - Glenmark Pharma shares surge 10% after its subsidiary signs $700 million licensing deal with AbbVie for ISB 2001 - Business Upturn
- 2 days ago - Top stocks in focus on July 11: Tata Steel, TCS, Tata Elxsi, Glenmark Pharma, HUL, JSW Infrastructure and more - Business Upturn
- 2 days ago - Glenmark shares in focus after $700 million AbbVie deal for ISB 2001 - Business Upturn
- 3 days ago - Glenmark Pharma’s subsidiary IGI Therapeutics signs $700 million licensing deal with AbbVie for ISB 2001 - Business Upturn
- 25 days ago - Glenmark receives five procedural observations from USFDA after Monroe facility inspection - Business Upturn
- 6 weeks ago - HSBC maintains buy on Glenmark Pharma, sees Rs 1,720 target; ISB 2001 deal key trigger - Business Upturn
- 6 weeks ago - Stocks to watch on May 27: CLSA, HSBC, Jefferies issue fresh views on Glenmark, Fusion, Nazara, AB Fashion, IT sector - Business Upturn